GlassScriptPhysician profile
Maykelyn Felipe
NPI 1528575925
$5,983.19
in general payments reported to CMS, 2019-2025
25 companies · $725 in 2025
The $725 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $893 · 2022: $1,078 · 2023: $1,427 · 2024: $1,859 · 2025: $725.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,000 · Education: $11.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,000.03 |
| Education | $11.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,672.71 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $602.01 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $501.25 | 2021-2025 | Fanapt, Hetlioz |
| Corium, LLC | $388.21 | 2023-2025 | Azstarys |
| Almatica Pharma LLC | $329.42 | 2022-2024 | Loreev Xr, Sertraline Hcl |
| Takeda Pharmaceuticals U.S.A., INC. | $300.78 | 2021-2024 | Trintellix |
| Lundbeck LLC | $253.27 | 2023-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $223.58 | 2023-2025 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $222.38 | 2021-2025 | Uzedy, Austedo Xr, Austedo |
| Alkermes, INC. | $218.31 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $207.09 | 2021-2025 | Caplyta |
| Orexo US, INC. | $204.26 | 2021-2024 | Zubsolv |
| Janssen Pharmaceuticals, INC | $200.87 | 2022-2025 | Invega Sustenna, Spravato |
| Braeburn INC. | $170.80 | 2023-2025 | Brixadi |
| Indivior INC. | $141.92 | 2021-2024 | Sublocade |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $80.96 | 2025 | Cobenfy |
| Eisai INC. | $68.40 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $38.61 | 2023 | Quviviq |
| Bausch Health US, LLC | $35.99 | 2021 | |
| Tempus Ai, INC | $26.78 | 2024 | |
| Axsome Therapeutics, INC. | $24.19 | 2022 | |
| Livanova USA, INC. | $23.62 | 2024 | Vns Therapy Symmetry Model 8103 Generator |
| Novo Nordisk INC | $17.00 | 2023 | Wegovy |
| Hikma Pharmaceuticals USA | $15.46 | 2022 | |
| Neos Therapeutics, LP | $15.32 | 2024 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maykelyn Felipe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.